ICER mulls GSK COPD drugs ahead of next Medicare negotiation

[cafead]

via The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

article source